IL164420A0 - Dry powder composition - Google Patents

Dry powder composition

Info

Publication number
IL164420A0
IL164420A0 IL16442004A IL16442004A IL164420A0 IL 164420 A0 IL164420 A0 IL 164420A0 IL 16442004 A IL16442004 A IL 16442004A IL 16442004 A IL16442004 A IL 16442004A IL 164420 A0 IL164420 A0 IL 164420A0
Authority
IL
Israel
Prior art keywords
dry powder
powder composition
composition
dry
powder
Prior art date
Application number
IL16442004A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL164420A0 publication Critical patent/IL164420A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16442004A 2002-04-13 2004-10-05 Dry powder composition IL164420A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0208608.0A GB0208608D0 (en) 2002-04-13 2002-04-13 Composition
PCT/GB2003/001542 WO2003088943A1 (en) 2002-04-13 2003-04-10 Dry powder compositions

Publications (1)

Publication Number Publication Date
IL164420A0 true IL164420A0 (en) 2005-12-18

Family

ID=9934855

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16442004A IL164420A0 (en) 2002-04-13 2004-10-05 Dry powder composition

Country Status (19)

Country Link
US (1) US20050244340A1 (https=)
EP (1) EP1494644A1 (https=)
JP (1) JP2005530733A (https=)
KR (1) KR20040099436A (https=)
CN (1) CN1658839A (https=)
AR (1) AR039409A1 (https=)
AU (1) AU2003217073A1 (https=)
BR (1) BR0309114A (https=)
CA (1) CA2481467A1 (https=)
GB (1) GB0208608D0 (https=)
IL (1) IL164420A0 (https=)
IS (1) IS7500A (https=)
MX (1) MXPA04010080A (https=)
NO (1) NO20044497L (https=)
PL (1) PL373294A1 (https=)
RU (1) RU2004130439A (https=)
TW (1) TW200404008A (https=)
WO (1) WO2003088943A1 (https=)
ZA (1) ZA200408245B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8337816B2 (en) 2001-09-17 2012-12-25 Glaxo Group Limited Dry powder medicament formulations
SE526509C2 (sv) * 2003-06-19 2005-09-27 Microdrug Ag Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd
EP1643974A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Inhalable pharmaceutical formulations comprising a sugar ester
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
PE20060272A1 (es) 2004-05-24 2006-05-22 Glaxo Group Ltd (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
WO2006066907A1 (en) * 2004-12-21 2006-06-29 Glaxo Group Limited Pharmaceutical formulations
MX2007009656A (es) * 2005-02-10 2007-11-07 Glaxo Group Ltd Proceso para elaborar lactosa utilizando tecnicas de clasificacion previa y formulaciones farmaceuticas formadas de la misma.
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
PL2046787T3 (pl) 2006-08-01 2011-10-31 Glaxo Group Ltd Związki pirazolo[3,4-b]pirydynowe i ich zastosowanie jako inhibitory PDE4
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
AU2014261538A1 (en) * 2013-04-29 2015-12-10 Sanofi Sa Inhalable pharmaceutical compositions and the inhaler devices containing them
AU2015296024A1 (en) * 2014-08-01 2017-03-23 Luxena Pharmaceuticals, Inc. Palonosetron formulations and uses thereof
PT109030B (pt) * 2015-12-15 2019-09-25 Hovione Farmaciência, S.A. Preparação de partículas inaláveis de zafirlucaste
CN110237373B (zh) * 2018-03-08 2023-06-02 润生药业有限公司 一种生产用于联合用药的药物载体的装置及方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR8007911A (pt) * 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
SE448277B (sv) * 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
JPH04220268A (ja) * 1990-12-19 1992-08-11 Olympus Optical Co Ltd バルーンカテーテル
ZA9711732B (en) * 1996-12-31 1998-12-28 Quadrant Holdings Cambridge Methods and compositions for improvement bioavailability of bioactive agents for mucosal delivery
PT994887E (pt) * 1997-07-03 2003-04-30 Elan Drug Delivery Ltd Glicosidos modificados composicoes que compreendem os mesmos e metodos para a sua utilizacao
US6352722B1 (en) * 1997-12-23 2002-03-05 Quadrant Holdings Cambridge Limited Derivatized carbohydrates, compositions comprised thereof and methods of use thereof
PL200941B1 (pl) * 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
GB9916316D0 (en) * 1999-07-12 1999-09-15 Quadrant Holdings Cambridge Dry powder compositions
GB0015981D0 (en) * 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
GB0020616D0 (en) * 2000-08-21 2000-10-11 Quadrant Holdings Cambridge Particulates
JP2004526674A (ja) * 2000-12-01 2004-09-02 バテル・メモリアル・インスティテュート 液体処方物中における生体分子の安定化のための方法
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
TW200404008A (en) 2004-03-16
BR0309114A (pt) 2005-02-01
AR039409A1 (es) 2005-02-16
KR20040099436A (ko) 2004-11-26
GB0208608D0 (en) 2002-05-22
IS7500A (is) 2004-10-11
MXPA04010080A (es) 2004-12-13
RU2004130439A (ru) 2005-06-10
CN1658839A (zh) 2005-08-24
ZA200408245B (en) 2007-03-28
EP1494644A1 (en) 2005-01-12
JP2005530733A (ja) 2005-10-13
NO20044497L (no) 2004-11-15
PL373294A1 (en) 2005-08-22
WO2003088943A1 (en) 2003-10-30
US20050244340A1 (en) 2005-11-03
AU2003217073A1 (en) 2003-11-03
CA2481467A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
GB0326632D0 (en) Dry powder formulations
EP1487524A4 (en) INHALER FOR DRY POWDER
ZA200405383B (en) Dry powder inhaler
GB0220467D0 (en) Composition
GB0213638D0 (en) Composition
EP1566419A4 (en) POWDER COATING
AU2003234909A1 (en) Powder composition
IL164421A0 (en) Dry powder inhalant composition
GB0203421D0 (en) Composition
IL164420A0 (en) Dry powder composition
GB0203280D0 (en) Anti-glycolytic composition
GB0211924D0 (en) Composition
GB2372518B (en) Powder composition
GB0218241D0 (en) Composition
EP1495751A4 (en) hair dye
GB0213767D0 (en) Composition
HK1074384A (en) Dry powder compositions
GB0306084D0 (en) Improved cosmetic composition
GB0203616D0 (en) Composition
HK1074783A (en) Dry powder inhalant composition
GB0213264D0 (en) Improved cosmetic composition
GB0200437D0 (en) Composition
GB0208301D0 (en) Composition
GB0209191D0 (en) Composition
GB0205293D0 (en) Composition